Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P13686
UPID:
PPA5_HUMAN
Alternative names:
Tartrate-resistant acid ATPase; Type 5 acid phosphatase
Alternative UPACC:
P13686; A8K3V2; Q2TAB1; Q6IAS6; Q9UCJ5; Q9UCJ6; Q9UCJ7
Background:
Tartrate-resistant acid phosphatase type 5 (TRAP5), also known as Type 5 acid phosphatase, plays a crucial role in osteopontin/bone sialoprotein dephosphorylation. Its expression is notably increased in various pathological states, including Gaucher and Hodgkin diseases, as well as several leukemias.
Therapeutic significance:
TRAP5 is directly implicated in Spondyloenchondrodysplasia with immune dysregulation, a disease marked by skeletal dysplasia and a strong predisposition to autoimmune diseases. This association highlights its potential as a target for therapeutic intervention in autoimmune and bone-related disorders.